← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	919	+44	+5%	$22B
2	2 Charles River Laboratories CRL $14.4B	252	-3	-1%	$2.95B
3	3 DELISTED bluebird bio BLUE	169	+46	+37%	$2.74B
4	4 DELISTED SANGAMO THERAPEUTICS INC SGMO	158	+1	+0.6%	$747M
5	5 PTC Therapeutics PTCT $4.98B	132	+33	+33%	$1.47B
6	6 Sarepta Therapeutics SRPT $1.78B	120	-3	-2%	$359M
7	ISEE 7 DELISTED IVERIC bio, Inc. Common Stock ISEE	116	+24	+26%	$1.36B
8	8 Precigen PGEN $2.63B	108	+6	+6%	$2.49B
9	9 Ultragenyx Pharmaceutical RARE $1.47B	100	0	0%	$1.23B
10	10 DELISTED CATALENT, INC. CTLT	94	+14	+18%	$3.27B
11	11 DELISTED Adverum Biotechnologies ADVM	84	+26	+45%	$727M
12	12 Lineage Cell Therapeutics LCTX $232M	59	+2	+4%	$114M
13	BLCM 13 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	55	+55	–	$308M
14	AGTC 14 DELISTED Applied Genetic Technologies Corporation AGTC	48	+6	+14%	$191M
15	ATHX 15 DELISTED Athersys, Inc. Common Stock ATHX	47	-1	-2%	$12M
16	16 DELISTED Carisma Therapeutics CARM	41	-1	-2%	$159M
17	17 Atara Biotherapeutics ATRA $96M	39	+39	–	$172M
18	18 Opus Genetics IRD $341M	38	+7	+23%	$5.65M
19	19 Fortress Biotech FBIO $63.4M	36	-3	-8%	$19.2M
20	20 Vericel Corp VCEL $2.06B	35	+4	+13%	$32.3M
21	21 Imunon IMNN $5.84M	33	-1	-3%	$7.58M
22	22 Pluri PLUR $11.7M	29	+2	+7%	$3.19M
23	23 uniQure QURE $1.45B	28	+2	+8%	$56.6M
24	24 Fate Therapeutics FATE $232M	23	+1	+5%	$51.7M
25	25 Neurogene NGNE $444M	22	0	0%	$31.2M